Memory-like differentiation enhances NK cell responses to melanoma
Clin Cancer Res, Marin et al, June 2021
Scientific Publications
Articles
Wugen: deploying memory NK cells against cancer
Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY
Press Releases
Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer
Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and
Articles
The Development of Natural Killer Cells for Solid Tumor Treatment
Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.
Articles
BioWorld: Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia
BioWorld, David Ho, March 2021.
Press Releases
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer
ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK)
Articles
St. Louis biotech startup Wugen inks manufacturing deal, hires C-suite exec
St. Louis Business Journal, Nathan Rubbelke, March 2021
Press Releases
Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer
ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms,
Press Releases
Wugen Announces the Appointment of Company’s Co-founder, Matt Cooper, Ph.D., as Chief Scientific Officer
ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced